Approximately 7% of acute myeloid leukemia (AML) harbors t(8;21), a core binding factor (CBF) lesion that leads to the RUNX1/RUNX1T1 (AML1/ETO) fusion gene and consequently the translation of an abnormal transcription factor that induces leukemogenesis [1]. Here, RUNX1T1 is linked to acute myeloid leukemia.